A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Jan 10, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the long-term effects of a treatment called ciltacabtagene autoleucel (often referred to as cilta-cel) in patients who have been previously treated for multiple myeloma, a type of blood cancer. The main goal is to gather information about any delayed side effects that might occur after receiving cilta-cel and to better understand how safe this treatment is over time.
To participate in this study, individuals must be between the ages of 65 and 74 and have already received at least one dose of cilta-cel in a previous clinical trial sponsored by the company. Participants will need to agree to be part of this new study by providing informed consent. Those who join can expect to share their health information and experiences related to the treatment, which will help researchers learn more about its long-term safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- • Participants who have provided informed consent for this study
About Janssen Research & Development, Llc
Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company dedicated to advancing innovative therapies in multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. With a strong commitment to scientific excellence and patient-centered research, Janssen leverages cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. The company is focused on addressing unmet medical needs through rigorous clinical trials and a robust pipeline, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Boston, Massachusetts, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
San Francisco, California, United States
Chicago, Illinois, United States
Bronx, New York, United States
Buffalo, New York, United States
Detroit, Michigan, United States
Saint Louis, Missouri, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Hackensack, New Jersey, United States
New York, New York, United States
Nashville, Tennessee, United States
Duarte, California, United States
Boston, Massachusetts, United States
Tampa, Florida, United States
Groningen, , Netherlands
Tel Aviv, , Israel
Indianapolis, Indiana, United States
New Brunswick, New Jersey, United States
Houston, Texas, United States
San Francisco, California, United States
Stanford, California, United States
Gent, , Belgium
Boston, Massachusetts, United States
Atlanta, Georgia, United States
Paris, , France
Amsterdam, , Netherlands
Pittsburgh, Pennsylvania, United States
Leuven, , Belgium
Nanjing, , China
Salamanca, , Spain
Westwood, Kansas, United States
Charlotte, North Carolina, United States
Shibuya, , Japan
Rochester, Minnesota, United States
Shanghai, , China
Beijing, , China
Tel Aviv, , Israel
Nagoya, , Japan
Pamplona, , Spain
Shanghai, , China
Chengdu, , China
Hangzhou, , China
Phoenix, Arizona, United States
Milwaukee, Wisconsin, United States
Xi'an, , China
Ramat Gan, , Israel
Fuzhou, , China
Shanghai, , China
Nagoya, , Japan
Chengdu, , China
Shanghai, , China
Shanghai, , China
Salamanca, , Spain
Nord, , France
Patients applied
Trial Officials
Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials